Enterprise value of Coherus BioSciences, Inc.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non?small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
|NIHD NII Holdings, Inc.||NASDAQ > Public Utilities > Telecommunications Equipment||$474.3M|
|NTRA Natera, Inc.||NASDAQ > Health Care > Medical Specialities||$474.97M|
|WTBA West Bancorporation||NASDAQ > Finance > Major Banks||$475.27M|
|HCCI Heritage-Crystal Clean, Inc.||NASDAQ > Basic Industries > Miscellaneous||$476.82M|
|MNKD MannKind Corporation||NASDAQ > Health Care > Major Pharmaceuticals||$477.87M|
|BPT BP Prudhoe Bay Royalty Trust||NYSE > Energy > Integrated oil Companies||$478.35M|
|CHRS Coherus BioSciences, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||$478.51M|
|HDB HDFC Bank Limited||NYSE > Finance > Commercial Banks||$527.41B|
|MSFT Microsoft Corporation||NASDAQ > Technology > Computer Software: Prepackaged Software||$663.03B|
|GOOG Alphabet Inc.||NASDAQ > Technology > Computer Software: Programming, Data Processing||$663.31B|
|GOOGL Alphabet Inc.||NASDAQ > Technology > Computer Software: Programming, Data Processing||$663.8B|
|AMZN Amazon.com, Inc.||NASDAQ > Consumer Services > Catalog/Specialty Distribution||$714.48B|
|AAPL Apple Inc.||NASDAQ > Technology > Computer Manufacturing||$920.16B|